Matches in SemOpenAlex for { <https://semopenalex.org/work/W2196675369> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2196675369 endingPage "3553" @default.
- W2196675369 startingPage "3553" @default.
- W2196675369 abstract "3553 Background: We conducted a phase I-II study with the triple drug combination FOLFOXIRI (irinotecan 125–175 mg/sqm day (d) 1, oxaliplatin 100 mg/sqm d1, l-LV 200 mg/sqm d1, 5-FU 3800 mg/sqm 48-h IV chronomodulated continuous infusion starting on d1, repeated every 2 weeks) and a subsequent phase II study with a simplified FOLFOXIRI regimen (irinotecan 165 mg/sqm d1, oxaliplatin 85 mg/sqm d1, l-LV 200 mg/sqm d1, 5-FU 3200 mg/sqm 48-h flat continuous infusion starting on d1, repeated every 2 weeks) respectively in 42 and 32 unselected MCRC pts with initially unresectable mts. Overall response rate, median progression free (PFS) and overall survival (OS) were 71% and 72%, 10.4 months (mos) and 10.8 mos, 26.5 mos and 28.4 mos respectively. Methods: In consideration of the high activity of these regimens 30 out of 74 pts (40%) could be revaluated for surgical resection of mts after chemotherapy. Among these 30 pts revaluated for surgery a R0 surgical resection could be performed in 19 pts (26% of the initial 74 pts). Characteristics of the 19 radically resected pts were: median age 66 years (45–73), ECOG PS ≥ 1 6 pts (32%), median CEA 10 ng/ml (1–288), median number of mts 3 (1–10), liver involvement ≥ 25% 12 pts (63%). Sites of disease were: liver only 14 pts, liver + lymphonodes 3 pts, liver + peritoneum 1 pt, liver + lung 1 pt. Mts were synchronous in 12 pts (63%) and metachronous in 7 pts with a median disease free interval of 12 mos. Results: After a median follow up of 28.8 mos median PFS is 18.6 mos and median OS is 39.6 mos. In 2 pts progressed after surgery a surgical re-resection and/or radiofrequency ablation was performed. Conclusions: First line FOLFOXIRI enables R0 surgical resection in about a quarter of pts with clearly initially unresectable MCRC. Median OS of resected pts is very promising. Prospective evaluation of FOLFOXIRI as neo-adjuvant treatment in initially unresectable colorectal cancer pts with liver and/or lung metastases is planned. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Pharma" @default.
- W2196675369 created "2016-06-24" @default.
- W2196675369 creator A5001205753 @default.
- W2196675369 creator A5012034272 @default.
- W2196675369 creator A5018418460 @default.
- W2196675369 creator A5055382594 @default.
- W2196675369 creator A5058514609 @default.
- W2196675369 creator A5072598658 @default.
- W2196675369 creator A5075851091 @default.
- W2196675369 creator A5081516681 @default.
- W2196675369 creator A5083540572 @default.
- W2196675369 creator A5084106899 @default.
- W2196675369 date "2004-07-15" @default.
- W2196675369 modified "2023-10-16" @default.
- W2196675369 title "Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC)" @default.
- W2196675369 doi "https://doi.org/10.1200/jco.2004.22.90140.3553" @default.
- W2196675369 hasPublicationYear "2004" @default.
- W2196675369 type Work @default.
- W2196675369 sameAs 2196675369 @default.
- W2196675369 citedByCount "5" @default.
- W2196675369 crossrefType "journal-article" @default.
- W2196675369 hasAuthorship W2196675369A5001205753 @default.
- W2196675369 hasAuthorship W2196675369A5012034272 @default.
- W2196675369 hasAuthorship W2196675369A5018418460 @default.
- W2196675369 hasAuthorship W2196675369A5055382594 @default.
- W2196675369 hasAuthorship W2196675369A5058514609 @default.
- W2196675369 hasAuthorship W2196675369A5072598658 @default.
- W2196675369 hasAuthorship W2196675369A5075851091 @default.
- W2196675369 hasAuthorship W2196675369A5081516681 @default.
- W2196675369 hasAuthorship W2196675369A5083540572 @default.
- W2196675369 hasAuthorship W2196675369A5084106899 @default.
- W2196675369 hasConcept C121608353 @default.
- W2196675369 hasConcept C126322002 @default.
- W2196675369 hasConcept C141071460 @default.
- W2196675369 hasConcept C2776694085 @default.
- W2196675369 hasConcept C2780259306 @default.
- W2196675369 hasConcept C2780456651 @default.
- W2196675369 hasConcept C2780962732 @default.
- W2196675369 hasConcept C2781413609 @default.
- W2196675369 hasConcept C526805850 @default.
- W2196675369 hasConcept C71924100 @default.
- W2196675369 hasConcept C90924648 @default.
- W2196675369 hasConceptScore W2196675369C121608353 @default.
- W2196675369 hasConceptScore W2196675369C126322002 @default.
- W2196675369 hasConceptScore W2196675369C141071460 @default.
- W2196675369 hasConceptScore W2196675369C2776694085 @default.
- W2196675369 hasConceptScore W2196675369C2780259306 @default.
- W2196675369 hasConceptScore W2196675369C2780456651 @default.
- W2196675369 hasConceptScore W2196675369C2780962732 @default.
- W2196675369 hasConceptScore W2196675369C2781413609 @default.
- W2196675369 hasConceptScore W2196675369C526805850 @default.
- W2196675369 hasConceptScore W2196675369C71924100 @default.
- W2196675369 hasConceptScore W2196675369C90924648 @default.
- W2196675369 hasIssue "14_suppl" @default.
- W2196675369 hasLocation W21966753691 @default.
- W2196675369 hasOpenAccess W2196675369 @default.
- W2196675369 hasPrimaryLocation W21966753691 @default.
- W2196675369 hasRelatedWork W1435255214 @default.
- W2196675369 hasRelatedWork W1985839252 @default.
- W2196675369 hasRelatedWork W2107769390 @default.
- W2196675369 hasRelatedWork W2112727687 @default.
- W2196675369 hasRelatedWork W2145139896 @default.
- W2196675369 hasRelatedWork W2145691940 @default.
- W2196675369 hasRelatedWork W2149091689 @default.
- W2196675369 hasRelatedWork W2339529025 @default.
- W2196675369 hasRelatedWork W2347320353 @default.
- W2196675369 hasRelatedWork W2766409029 @default.
- W2196675369 hasVolume "22" @default.
- W2196675369 isParatext "false" @default.
- W2196675369 isRetracted "false" @default.
- W2196675369 magId "2196675369" @default.
- W2196675369 workType "article" @default.